Company profile: NeuroPace
1.1 - Company Overview
Company description
- Provider of implantable neurostimulation devices for neurological disorders, featuring the FDA-approved RNS System for epilepsy to monitor brain activity, detect unusual patterns, and deliver responsive pulses to prevent seizures. Offers personalized neuromodulation based on patient brain activity, the nSight platform for remote data access, and clinical studies (NAUTILUS, RESPONSE, and other RNS System trials).
Products and services
- NSight Platform: A remote-access-capable platform that simplifies the RNS System data experience, enabling remote access to patient data to support personalized epilepsy care
- Personalized Neuromodulation Therapy: A patient-specific approach that delivers stimulation based on each patient's unique brain activity to prevent seizures in epilepsy
- RNS System: An FDA-approved neurostimulation device for epilepsy that monitors brain activity, detects unusual patterns, and responds with targeted electrical pulses to prevent seizures
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeuroPace
Grass Technologies
HQ: United States
Website
- Description: Provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders; designs and develops leading-edge products in neurology and other life science markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grass Technologies company profile →
Abliva
HQ: Sweden
Website
- Description: Provider of medicines for primary mitochondrial diseases—congenital, rare and often severe conditions resulting from mitochondrial dysfunction. Portfolio spans early discovery to clinical phases. Pipeline includes KL1333 to address symptoms such as chronic fatigue and muscle weakness, and NV354 for diseases with neurological complications, including Leigh syndrome and MELAS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abliva company profile →
Winston Labs
HQ: United States
Website
- Description: Provider of pain management products, engaged in their development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Winston Labs company profile →
T3D Therapeutics
HQ: United States
Website
- Description: Provider of remedial therapeutics for Alzheimer's disease and other CNS disorders, including T3D-959, an investigational oral drug candidate designed to treat Alzheimer's by improving brain glucose and lipid metabolism, potentially addressing multiple disease manifestations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3D Therapeutics company profile →
Axsome Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for neurological disorders, including Auvelity for major depressive disorder and Sunosi to improve wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea or narcolepsy; developing AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-07 for acute migraine, and AXS-12 for narcolepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axsome Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeuroPace
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeuroPace
2.2 - Growth funds investing in similar companies to NeuroPace
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeuroPace
4.2 - Public trading comparable groups for NeuroPace
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →